NASUS PHARMA LTD
Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$3.07
-3.76%
Alpha Vantage · 10/30/2026
One-year price history
Adjusted daily closes · 252 observations · as of Oct 30, 2026
1 month
-19.5%
3 months
-3.8%
6 months
+11.6%
1 year
-60.5%
Year to date
-66.5%
52-week range
$2.01 – $9.15
Fundamental snapshot
Latest reported period: Jun 30, 2026
Market cap
$36M
P/E
-3.4
P/B
3.3
P/S
—
Revenue
$0
Net income
-$10.55M
Diluted EPS
-1.09
Gross margin
—
Net margin
—
Return on equity
-315.70%
Total debt
$103K
Cash
$7.9M
Free cash flow
-$10.53M
Latest eight reported quarters
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Jun 30, 2026 | — | — | — | — | — |
| Dec 31, 2025 | — | — | — | — | — |
| Jun 30, 2025 | — | — | — | — | — |
| Dec 31, 2024 | — | — | — | — | — |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Recent NSRX news
All market newsNo ticker-linked stories are in the current archive.